Apotex Health Corp. APTX

Apotex Health Corp. (TSX: APTX) ("Apotex" or the "Company") announced today that it has priced a private placement offering (the "Offering") of $1,250 million aggregate principal amount of senior unsecured notes in three series (the "Notes"), consisting of $400 million aggregate principal amount of 4.390% senior unsecured notes, Series 1 due October 5, 2029, $550 million aggregate principal amount of 4.769% senior unsecured notes, Series 2 due October 5, 2031 and $300 million aggregate principal

Apotex Health Corp. ("Apotex" or the "Company") announced today the closing of the previously announced upsized secondary offering (the "Offering") of common shares of the Company (the "Common Shares") by an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders").

Apotex Health (TSX:APTX) is back in focus after selling shareholders moved to increase a previously announced bought deal secondary offering to 25,000,000 common shares at CA$34.00, with an additional over allotment option. Recent trading paints a mixed picture for Apotex Health. The share price return has climbed 18.95% over the past 90 days and 23.22% year to date, although the 1 day share price return of 9.35% following the upsized secondary offering signals some cooling momentum as...

Apotex Health Corp. ("Apotex" or the "Company") announced today that, as a result of strong demand, Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an amended agreement with the syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets

Apotex Health Corp. ("Apotex" or the "Company") announced today that Apotex, an affiliate of SK Capital Partners ("SK Capital"), API Investment LP ("Sherfam") and Allan Oberman ("Oberman", and together with SK Capital and Sherfam, the "Selling Shareholders") have entered into an agreement with a syndicate of underwriters (the "Underwriters") led by RBC Capital Markets, TD Securities Inc., and Scotiabank, as joint lead bookrunners, and BMO Capital Markets and Jefferies Securities, Inc., as joint

RedHill Biopharma Ltd. (NASDAQ: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the divestment of its Talicia business to a subsidiary of Apotex Health Corp. (TSX: APTX) ("Apotex") for an upfront payment of $18 million plus up to an additional $35 million in potential payments based on worldwide net sales milestones.

Company closes $100M Apotex deal, declares special dividend, and advances key clinical programs including DMD, systemic sclerosis, and IPF.

Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a U.S. biopharmaceutical company, today announced the closing on an agreement with subsidiary of Apotex Health Corp. ("Apotex"), the largest Canadian-based pharmaceutical company, to integrate their branded U.S. businesses. Under the terms of the agreement, Apotex has acquired Cumberland's line of branded pharmaceuticals for cash consideration of $100 million funded at closing, which followed approval by Cumberland's shareholders.

Apotex Health Corp. ("Apotex" or the "Company") (TSX: APTX), the largest Canadian-based global health company, today announced it is the first to receive Health Canada's approval for a generic equivalent of Wegovy® (semaglutide injection) for chronic weight management in adults.

Apotex Health stock: key metrics at a glance Apotex Health (TSX:APTX) slipped about 1.3% in the latest session to CA$28.60, drawing attention to how investors might weigh its current valuation, earnings profile, and business mix across generics, biosimilars, and branded products. See our latest analysis for Apotex Health. The 1 day share price return of 1.35% and year to date share price return of 5.93% suggest steady but not aggressive momentum, which fits with a stock where valuation and...

Toronto, Ontario--(Newsfile Corp. - June 11, 2026) - Jeff Watson, President and Chief Executive Officer, Apotex Health Corp. (Apotex) (TSX: APTX) along with its Board of Directors, executive team, partners and employees, joined John McKenzie, Chief Executive Officer, TMX Group, to open the market to celebrate its new listing on Toronto Stock Exchange.Cannot view this video? Visit:https://www.youtube.com/watch?v=rPKtnnRI8Q4As a Canadian-based global health company, Apotex improves everyday...

TSX celebrates largest life sciences IPO by total proceeds raised with market open ceremonyToronto, Ontario--(Newsfile Corp. - June 10, 2026) - Toronto Stock Exchange (TSX) announced today that Apotex Health Corp. (Apotex), a Canadian-based global health company, will begin trading today under the symbol TSX: APTX.To celebrate the listing, Jeff Watson, President and CEO, Apotex, will join John McKenzie, CEO, TMX Group, to open trading on Thursday, June 11, at 9:30 a.m ET. Apotex's IPO is...